Introducing the "FYT Search Tool" and Clinical Trials Updates

Clinical Trials e-Newsletter | March 2019

Clinical Trials e-Newsletter

PHEN has developed and introduced a new tool aimed at connecting patients with actively recruiting prostate cancer clinical trials that could benefit them. All trials listed have links to important information, including study locations, contacts and more. The trials listed in the FYT tool are broken down into six easily searchable categories for patients to view and use to find a clinical trial that is right for them based on where they are on their prostate cancer journey. Find Your Trial Here:

Talapro-1 Clinical Trial

This clinical trial is for patients with metastatic Castration Resistant Prostate Cancer who have

certain mutations (BRCA1, BRCA2 & others) and previously received chemotherapy and have

progressed on enzalutamide or abiraterone.

Patient summary for this trial.

Talapro-2 Clinical Trial

This clinical trial is for patients with metastatic Castration Resistant Prostate Cancer who have not received prior treatment for their disease. The purpose of this study is to compare the use

of the PARP-inhibitor talazoparib plus enzalutamide to treat eligible patients to the use of enzalutamide alone.

Patient summary for this trial.

CA209-9KD Clinical Trial

This is a clinical research study for men with metastatic prostate cancer that no longer

responds to treatments that lower testosterone. The enrollment period for this study has recently

been extended, allowing for men to continue

registering for participation.

Patient summary for this trial.

Understanding Castration Resistant Prostate Cancer

Androgen deprivation (hormone) therapy, such as Lupron, works to reduce testosterone in the body to castration levels to prevent or slow the progression of prostate cancer.